Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology.
The last earnings update was 40 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Protagonist Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Protagonist Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Protagonist Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
Protagonist Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Protagonist Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Protagonist Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Protagonist Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Protagonist Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Protagonist Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Protagonist Therapeutics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Dinesh V. Patel, Ph.D., has been the Chief Executive Officer and President at Protagonist Therapeutics, Inc. since December 2008 and its Interim Chief Financial Officer since January 11, 2019. Dr. Patel serves as secretary of Protagonist Therapeutics, Inc. Dr. Patel served as Consultant of Arête Therapeutics, Inc. since July 2008. He served as Chief Executive of Arête Therapeutics Inc., from February 2006 to July 2008 and also served as its President since 2006 until July 2008. Dr. Patel Co-founded Miikana Therapeutics Inc., in 2002 and served as its President from 2003 to 2005 and served as its Chief Operating Officer. He served as Senior Vice President of drug discovery and licensing of Vicuron Pharmaceuticals Inc., (formerly, Versicor) since 1996 until July 2003. Dr. Patel has over 18 years of experience in the pharmaceutical, biotech and biopharmaceutical industry. Prior to Miikana, Dr. Patel held positions of increasing responsibility at Versicor (later renamed Vicuron and which was acquired by Pfizer in 2015), from 1996 to 2003. At Versicor, he led their internal and collaborative research programs (Pharmacia, Novartis) and actively participated in various financing activities. Dr. Patel served as Director of Drug Discovery of Affymax and led the combinatorial chemistry application efforts aimed at changing the drug discovery paradigm. Dr. Patel was a medicinal chemist at BristolMyers Squibb from 1985 to 1193 and served in various positions including group leader. Dr. Patel has a proven track record of incubating and leading projects from ‘Targets to INDs’. He serves as a Director of Protagonist Therapeutics, Inc. since December 2008. He served as Director of Arête Therapeutics, Inc. until July 2008. He has more than 100 patents and publications to his credit. Dr. Patel was a director of chemistry at the combinatorial chemistry company Affymax, from 1993 to 1996. Prior to that, he was the Chief Executive Officer of Miikana Therapeutics, an oncology-based company, from 2003 until it was acquired by Entremed (later renamed CASI Pharmaceuticals) in 2005. Dr. Patel has more than 30 years of executive, entrepreneurial and scientific experience spanning the pharmaceutical, biotechnology and biopharmaceutical industries. Dr. Patel received his Ph.D. in Organic Chemistry from Rutgers, The State University of New Jersey and conducted Post-Doctoral research at the University of Wisconsin, Madison. He holds B.S. in Industrial Chemistry from S. P. University, Vallabh Vidyanagar, India.
Dinesh's compensation has been consistent with company performance over the past year.
Dinesh's remuneration is about average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Protagonist Therapeutics management team is about average.
Chief Medical Officer
Chief Scientific Officer and Head of Research & Development
Vice President of Technology
Chief Development Officer
Executive Vice President of Clinical Operations & Clinical Pharmacology
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Protagonist Therapeutics board of directors is about average.
Board of Directors
Director & Chairman of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
Protagonist Therapeutics insiders have only sold shares in the past 3 months.
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD. It is also involved in researching oral and injectable peptide-based product candidates for a range of conditions, including gastrointestinal diseases. The company was founded in 2006 and is headquartered in Newark, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.